Skip to main content

X4 Pharmaceuticals Announces FDA Approval of Mavorixafor, First Drug Indicated in Patients with WHIM Syndrome

Former TAP Partner


BOSTON, April 29, 2024 - X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

Paula Ragan, CEO of X4 Pharmaceuticals

Paula Ragan
CEO, X4 Pharmaceuticals

“The early LLS TAP partnership and support for X4 was critical for our company’s success. The TAP team’s important contributions have helped X4 achieve a new day for WHIM patients. Thank you, LLS!”

Press Release